Theme: Models of Care Year: 2018
Addiction-services providers (ASPs) and community-based hepatitis C virus (HCV) treaters
have knowledge deficits and practices that impact the engagement, referral, and treatment of
HCV-positive people who inject drugs (PWID). The BRIDGE HCV pilot created parallel
education tracks designed to (1) increase HCV testing/referral by ASPs; (2) prepare treaters to
provide treatment for HCV-positive PWID; and (3) promote harm-reduction principles to prevent
HCV reinfection. The goal of the BRIDGE HCV initiative is to build local networks of ASPs and
HCV treaters to support HCV microelimination.
Description of model of care/intervention:
BRIDGE HCV launched in 2017 with 8 1-hour training meetings for ASPs and 5 2-part, smallgroup, training sessions (1 hour each) for HCV treaters. 162 ASPs at 8 addiction-treatment
centers and 174 HCV treaters at 5 community clinics participated. Pre-/post-training multiplechoice and rating-scale questions assessed change in knowledge and intention to refer/treat
patients with HCV.
HCV knowledge scores increased 103% from baseline for ASPs (4 questions; 32% correct pretraining [n=194], 65% correct post-training [n=163]; P<.001). ASPs’ frequency of referring HCVantibody–positive PWID for confirmatory testing/treatment increased 380.0% (15% referred clients pre-training [n=111], 72% planned to refer clients post-training [n=111]; P<.001). Knowledge increased 40.4% from baseline for HCV treaters (5 questions; 47% correct pretraining [n=162], 66% correct post-training [n=48]; P=.021). HCV treaters’ frequency of prescribing DAA therapy to PWID increased 151.6% from baseline (31% of providers treated PWID pre-training [n=165], 78% of providers planned to treat PWID post training [n=53]; P<.001). Conclusion and next steps: Increased knowledge and intention to refer/treat PWID with HCV were found in ASPs and HCV treaters who completed BRIDGE HCV small-group training sessions. Based on these results, the initiative will expand to Baltimore, MD, and The Bronx, NY, in 2018. Future analyses will compare BRIDGE vs non-BRIDGE sites’ rates of testing, referral, and sustained virologic response. Disclosure of Interest Statement: The BRIDGE HCV initiative is supported by educational grants from Gilead Sciences, Inc. and Merck & Co., Inc. to Purdue University College of Pharmacy, with Integritas Communications, LLC as an educational partner. Jody Gilmore has been a speakers’ bureau participant and received honoraria from AbbVie Inc., and Gilead Sciences, Inc. Stacey Trooskin has received grants/research support from Gilead Sciences, Inc. Jeanette Ruby and Becky Carney are employed by Integritas Communications, LLC.